Marlene Wullt* and Inga Odenholt. Department of Infectious Diseases, University Hospital, Malmö, Sweden
|
|
- Lionel Bertram Marshall
- 6 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2004) 54, DOI: /jac/dkh278 Advance Access publication 26 May 2004 A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea Marlene Wullt* and Inga Odenholt Department of Infectious Diseases, University Hospital, Malmö, Sweden JAC Received 17 November 2003; returned 16 January 2004; revised 2 April 2004; accepted 13 April 2004 Objectives: Few treatment options are currently available to treat patients suffering from an initial episode of Clostridium difficile-associated diarrhoea (CDAD). Patients and methods: A prospective, randomized controlled, double-blind trial was conducted to compare the efficacy of fusidic acid and metronidazole for treatment of patients experiencing a first episode of CDAD. The primary outcomes were clinical cure and clearance of determined on days 8 13, and secondary outcomes were clinical recurrence and reappearance of evaluated on days Results: Of the patients in the fusidic acid group, 83% were clinically cured in comparison to 93% in the metronidazole group (P ) at the first follow-up visit. Clearance of did not differ between the two groups at that time. Clinical recurrence and reappearance of were noted in 27% and in 13% of the patients receiving fusidic acid, respectively and in 29% and 10% of those given metronidazole at the second follow-up on days Conclusion: Since three of the four primary and secondary outcomes were almost identical for the two groups, the results indicate that fusidic acid is as effective as metronidazole in curing an initial episode of CDAD and can therefore be considered as an adequate alternative for treatment of this disease. Keywords: antibiotics, alternative treatments, toxins, pseudomembranous colitis Introduction Clostridium difficile-associated diarrhoea (CDAD) constitutes an increasing problem in hospitals, and it primarily affects elderly patients with chronic diseases and surgical patients. 1 6 CDAD is associated with a variety of symptoms ranging from mild diarrhoea through moderately severe disease to pseudomembranous colitis. 7 Most patients experiencing a first episode of CDAD are cured by treatment with metronidazole or vancomycin. 8 However, the latter drug should no longer be considered as a first-line treatment due to the increasing incidence of vancomycin-resistant enterococci (VRE), which essentially leaves only metronidazole in the treatment of CDAD. Fusidic acid has been found to be effective against C. difficile in vitro. 9,10 Moreover an earlier open, non-blinded study had demonstrated that fusidic acid is adequately effective in the treatment of CDAD. 11 However, Wenisch et al. 12 later reported that fusidic acid offers inferior, but not statistically significant, clinical and microbiological efficacy for treatment of CDAD. Since the results of Wenisch et al. did not agree with our clinical experiences, this was the incentive to test fusidic acid in a larger investigator-initiated trial. To our knowledge, this is the first study to be focused solely on patients with an initial episode of CDAD and it is also hitherto the largest trial to examine the effectiveness of fusidic acid for the treatment of such patients. Materials and methods Study population and design The study was carried out at two university hospitals and seven general hospitals in southern Sweden from September 1999 to May Inpatients and outpatients in all departments of the hospitals were enrolled. The local Microbiology Laboratories daily informed the respective investigator teams of all positive... *Corresponding author. Tel: ; Fax: ; marlene.wullt@skane.se JAC vol.54 no.1 q The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
2 M. Wullt and I. Odenholt assays. Enrolment was done by the investigator teams at the Departments of Infectious Diseases. Criteria for inclusion in the study were age >18 years, lack of hypersensitivity to fusidic acid or metronidazole, a positive assay from faeces within 6 days before enrolment (toxins A and B; ELISA, Premier EIA, Meridian Diagnostics, USA), and a history of ongoing diarrhoea (diarrhoea defined as three or more loose stools per day for at least 2 days). Exclusion criteria comprised the following: a prior clinically and microbiologically established episode of C. difficile diarrhoea within the previous 6 months, pregnancy, severe or concomitant medical conditions such as AIDS and metastatic cancer and the risk of non-compliance with the study protocol. Ongoing treatment with metronidazole, vancomycin, fusidic acid, or teicoplanin was also an exclusion criterion, and further treatment with these drugs was not allowed during the study period. Informed consent was obtained from all patients. The investigation was approved by the respective regional Medical Ethics Committees. Treatment protocol and interventions On enrolment day, a medical history was taken that included prior and ongoing symptoms, complete history of previous and ongoing antibiotics, earlier hospitalization, underlying diseases, interventions undergone, and other medications of importance (Table 1). Patients were randomized to fusidic acid 250 mg orally three times daily or to metronidazole 400 mg orally three times daily for 7 days. The first day of intake of the study medication was defined as day 1. Patients were asked to keep a diary covering the frequency and consistency of diarrhoea, presence or absence of other symptoms, side effects, and intake of the study medication. Follow-up visits were conducted on days 8 13 and In cases of clinical failure or clinical recurrence, the patients were seen at follow-up visits within 2 days and then left the study without further follow-up. At follow-ups, medical history was taken, and stool samples were collected for later analysis of toxins A and B. Toxin assays were carried out at the Clinical Microbiology Laboratory at each centre. Randomization The study medication was delivered from Leo Pharma AB, Malmö, Sweden, in coded blister packs, each containing a daily dose of six capsules (metronidazole 200 mg 2 3 or placebo) or three tablets (fusidic acid 250 mg 3 or placebo). The placebo capsules and tablets did not differ in form or colour from the active counterparts. An independent statistician provided a computer-generated list of random set numbers. The investigator teams were unaware of the treatment allocation. Outcomes Primary outcomes were clinical cure and clearance of C. difficile toxin at the first follow-up (days 8 13). Clinical cure was defined Table 1. Baseline characteristics of the study population (n =131) and the 114 evaluable patients in both treatment groups Fusidic acid Metronidazole Intention-to-treat Characteristic (n=59) (n=55) (n=131) Mean (S.D.) age (years) 58.0(18.7) 58.4(18.2) 59.0(18.2) Gender (female/male) 41/18 33/22 80/51 Inpatient on enrolment 27(46) 28(51) 67(51.5) Outpatient on enrolment 32(54) 27(49) 64(49) Duration of diarrhoea before treatment mean (days) 22.3(35.1) 19.6(28.3) 22.4(36.4) median (days) quartiles 11(6.22) 9(5.18) 10(5.20) No. of bowel movements/24 h (32) 16(29.6) 45(35) (49) 24(43.6) 60(45.8) (10) 11(20) 17(13) >15 5(8) 4(7) 9(7) Fever (>37.98C) 14(24) 15(27) 34(26) Abdominal pain 40(69) 35(63) 82(63) Vomiting 12(20) 12(22) 28(21) Nausea 32(52) 23(42) 65(50) Underlying conditions cardiovascular/hypertensive 22(37) 15(27) 45(34) diabetes mellitus 5(8) 8(14) 14(11) acid-peptic disease 13(22) 9(16) 24(18) renal disease 6(10) 1(2) 7(5) hepatic disease 3(5) 2(4) 5(4) malignancy 8(14) 6(11) 17(13) chronic respiratory disease 2(3) 6(11) 12(9) inflammatory bowel disease 3(5) 2(4) 5(4) Surgery within last 4 weeks 8(14) 12(22) 22(17) Prior hospitalization 13(28) 13(34) 28(29) Prior antibiotic treatment 44(75) 42(76) 86(75) Ongoing antibiotic treatment 10(17) 9(16) 19(17) Values indicate numbers (percentages) unless stated otherwise. Note: There were no significant differences between the two treatment groups in terms of clinical features. 212
3 Treatment of CDAD as the cessation of diarrhoea within 5 8 days of initiating treatment, and clinical failure as persistence of diarrhoea on days 5 8. Persistence of was defined as a positive assay for on days Secondary outcome was clinical recurrence, defined as the reappearance of diarrhoea on days 8 40 in clinically cured patients who had completed 7 days of treatment. The criterion for reappearance of was detection of on days 35 40, after a negative toxin assay on days A positive assay at the first and second follow-ups was categorized as chronic persistence of C. difficile toxin, whereas a positive toxin assay on days 8 13 and a negative assay on days was classified as late clearance of C. difficile toxin. Side effects were tertiary outcomes. Statistical analysis We analysed the results both by intention-to-treat and per protocol. We used Fisher s test, x 2 test, and Mann Whitney U-test to determine statistical significance. Odds ratios with 95% confidence intervals were calculated according to Mantel Haenszel. A P value less than 0.05 was considered significant. The primary objective of the study was to demonstrate the non-inferiority of fusidic acid compared to metronidazole for the clinical cure of CDAD and clearance of on days With a postulated cure rate of 90%, the planned study population was 150 patients in each group in order to detect an absolute difference of 10% with a power of 80% and a 5% significance level. Figure 1. Design of randomized, double-blind, placebo-controlled trial to compare the efficacy of fusidic acid and metronidazole for treatment of patients experiencing a first episode of CDAD. 213
4 M. Wullt and I. Odenholt Results Altogether 131 patients could be enrolled and randomized according to the protocol. Of these, 114 patients were evaluable, 59 randomly assigned to treatment with fusidic acid and 55 to metronidazole (Figure 1). The two treatment groups were comparable with respect to baseline characteristics (Table 1). Table 2 illustrates clinical and microbiological outcomes for both treatment groups. The proportion of patients clinically cured on days 8 13 was 83% in the fusidic acid group and 93% in the metronidazole group (OR = 0.38; 95% CI ; P = 0.116). The rate of persistence of was similar for the two groups (22% and 23%, respectively; P = 0.939). The results at the second follow-up were also similar for the two treatment groups. Clinical recurrence and reappearance of were noted in 27% and 13% of the patients receiving fusidic acid, respectively and in 29% and 10% of those given metronidazole. Five patients in the fusidic acid group and eight in the metronidazole group experienced side effects, primarily abdominal pain (three in each group) and nausea (one taking fusidic acid and three metronidazole). Other side effects were headache Table 2. Primary and secondary outcomes in prospective, randomized controlled, double-blind trial to compare the efficacy of fusidic acid and metronidazole for treatment of patients experiencing a first episode of CDAD Fusidic acid Metronidazole Follow-up n = 59 (%) n=55 (%) P value a Days 8 13 Clinical effect b Cure 49(83) 51(93) Failure 10(17) 4(7) Bacteriological effect c Clearance of 46(78) 41(77) Persistence of 13(22) 12(23) Days Clinical effect d No recurrence 33(73) 35(71) Recurrence 14(27) 15(29) Bacteriological effect e Permanent clearance of 32(70) 34(68) Late clearance of 4(9) 3(6) Reappearance of 6(13) 5(10) Chronic persistence of 4(9) 8(16) Values represent numbers (percentages) of patients. a x 2 test. b Patients with a clinical failure, who left the study and were not further evaluated. c Faecal samples from two patients were missing for analysis in the metronidazole group. d Two patients in the fusidic acid group and one patient in the metronidazole group left the study before the second follow-up. e Faecal sample from one patient was missing for analysis in the fusidic acid group. (one receiving fusidic acid), exanthema (one taking metronidazole), and metallic taste (one given metronidazole). Discussion This study showed that there was no statistically significant difference in clinical and bacteriological cure rate between the two treatment groups. There was a tendency towards a higher frequency of clinical failure in the fusidic acid group compared with the metronidazole group, but this was not correlated with the rate of persistence of. A possible explanation for this is that the degree of illness indicated by current symptoms (such as duration of diarrhoea before enrolment, abdominal pain, nausea and underlying diseases) seemed to be more severe in patients taking fusidic acid than in those on metronidazole, although the observed differences were not statistically significant. Interestingly, the rate of chronic persistence of was higher in the metronidazole group (16%) than in the fusidic acid group (9%). This difference was not statistically significant, but it may prove to be of interest in the future when considering the risk of recurrences of CDAD. Response to therapy was rapid and within 5 days of the onset of therapy for both drugs (data not shown), which agrees with findings reported by other investigators. 13,14 No investigations that have focused on treatment of uncomplicated CDAD have provided statistically significant evidence that one antibiotic treatment is superior to another. 15 Moreover, most studies, especially those with alternative agents like bacitracin and teicoplanin have not been large enough to yield statistically significant data and have not dealt exclusively with patients experiencing a first episode of CDAD. 12,13,16 18 The impact of fusidic acid on CDAD has been examined in two earlier trials. 11,12 Cronberg et al. carried out an unblinded study to compare fusidic acid (various regimens of g daily) with metronidazole and vancomycin for treatment of CDAD. 11 These investigators noted a cure rate of 75% for fusidic acid and similar rates for metronidazole and vancomycin, a level that is markedly lower than observed in our study. However, they also included patients with recurrent episodes of CDAD. Wenisch et al. compared the efficacy of fusidic acid, metronidazole, vancomycin and teicoplanin in treatment of CDAD in 126 patients. 12 The investigated regimens represented higher doses and a longer duration of treatment than applied in our study and led to clinical cure rates of 93 96%, which were higher than those we achieved with fusidic acid and comparable to our results with metronidazole. Wenisch et al. also observed a percentage rate of clinical recurrence of 28% in the fusidic acid group, which agrees with our findings but is higher than the rates these investigators reported for the other treatment agents (16% for metronidazole and vancomycin and 7% for teicoplanin). However, differences between the recurrence rates were not statistically significant, except for teicoplanin versus fusidic acid (P = 0.042) and they noted that the percentage of positive cytotoxin assays 30 days after treatment was not significantly higher for the patients who had taken fusidic acid than for those who had been given metronidazole. They also found that patients with endoscopically confirmed pseudomembranous colitis showed similar results regardless of whether they had received fusidic acid or metronidazole. It was not stated in the paper whether recurrent cases of CDAD had been enrolled. 214
5 Treatment of CDAD Other studies that have investigated metronidazole in comparison with other agents such as vancomycin, have found similar clinical cure rates for metronidazole as in our study. 13,19 Approximately 20% of all cases of CDAD usually resolve spontaneously when the precipitating antibiotic is withdrawn. 8 However, only 17% of the patients included in our study (considering both treatment groups) were undergoing antibiotic treatment at the time of enrolment and most of the subjects had underlying conditions that required specific treatment for CDAD. Also, since symptomatic patients with CDAD are considered as a source for nosocomial spread of C. difficile, it is reasonable to treat these patients at the time of laboratory diagnosis. 8 Both metronidazole and vancomycin have drawbacks. Nausea frequently occurs during treatment with metronidazole, and pregnancy has been considered to be a contraindication for the use of this drug. 19,20 Decreased susceptibility of C. difficile to metronidazole has also been observed Considering vancomycin, a significant association has been found between vancomycin treatment of CDAD and VRE infection or colonization. 24 This may result in vancomycin-resistant strains of C. difficile, which poses new challenges in the management of CDAD. 25 As a result of the growing concern that widespread use of vancomycin will lead to increased resistance in enterococci, this drug should be saved as an alternative for treatment of recurrent disease. 8,26 Fusidic acid has a limited spectrum of activity and is effective mainly against Gram-positive bacteria; most Bacteroides spp. are resistant or only modestly sensitive and Gram-negative bacteria are completely resistant to this drug. 9,27 In contrast, metronidazole has an antimicrobial spectrum focused primarily on anaerobic bacteria such as Bacteroides spp. 28 It has been suggested that the absence of Bacteroides spp. in the colonic microflora of patients with CDAD can give rise to chronic relapsing CDAD. 28,29 In other words, the presence of Bacteroides spp. in the gut may prevent colonization of C. difficile, which might be an advantage for fusidic acid. Although selection of resistant bacteria during treatment with fusidic acid has been documented previously both in vitro and in vivo, it does not seem to occur at high frequency in clinical practice. 30,31 The resistance rates of Gram-positive bacteria against fusidic acid have remained low in all parts of the world, even in countries with a high consumption of fusidic acid (Denmark) 32 with the exception of a clonal spread of an impetigo strain resistant to fusidic acid in Scandinavia, which, however, is not considered to be due to an overuse of fusidic acid. 33 A major impetus for our study was the knowledge that earlier clinical experience of fusidic acid for treatment of CDAD had been satisfactory. To minimize the ecological impact of the drugs, we used lower doses and a shorter duration of treatment than had been employed in previous investigations. Concerning costs for a 7 day course of treatment, metronidazole is the cheapest ( 8.2), followed by fusidic acid ( 13) and vancomycin (125 mg 4) ( 66). Few options are currently available to treat patients suffering from CDAD. Even though we did not reach the planned sample size mainly due to spontaneous cure of diarrhoea, already initiated treatment for CDAD and risk for non-compliance, our investigation does include a large number of patients. There was a tendency towards a higher frequency of clinical failure in the fusidic acid group on days 8 13, but no difference in clearance of toxin was seen at that time. Also, there were no differences in clinical and bacteriological outcome on days Therefore, fusidic acid can be considered as an adequate alternative to metronidazole for treatment of initial episodes of CDAD. Conflict of interest statement None. Acknowledgements We are grateful to Stig Cronberg for help in initiating the study and Jan-Åke Nilsson for help with the statistics. We also thank all participating investigators at the Departments of Infectious Diseases at hospitals in southern Sweden: in Helsingborg, Katrin Arnvik, Anna-Karin Larsson, and Bushra Ibrahim-Baker; in Jönköping, Peter Iveroth and Jesper Svefors; in Karlskrona, Ingrid Lindblad and Carl-Johan Fraenkel; in Kristianstad, Karin Sjöbeck and Mattias Waldeck; in Lund, Karin Norlin and Gisela Otto; in Skövde, Lars Ljungström and Erik Backhaus; in Växjö, Per Dahl; in Örebro, Torbjörn Norén. This study was supported by grants from Region Skåne and the Scandinavian Society of Antimicrobial Chemotherapy, and by Leo Pharma AB, Malmö, Sweden, who also delivered the study medication. References 1. Wilcox, M. H. (1996). Cleaning up Clostridium difficile infection. Lancet 348, Jones, E. M. & MacGowan, A. P. (1998). Back to basics in management of Clostridium difficile infections. Lancet 352, Wilcox, M. H. (1998). Clostridium difficile setting the scene. Journal of Antimicrobial Chemotherapy 41, Suppl. C, Kyne, L., Sougioultzis, S., McFarland, L. V. et al. (2002). Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhoea. Infection Control and Hospital Epidemiology 23, Morris, A. M., Jobe, B. A., Stoney, M. et al. (2002). Clostridium difficile colitis: an increasingly aggressive iatrogenic disease? Archives of Surgery 137, Simor, A. E., Bradley, S. F., Strausbaugh, L. J. et al. (2002). Clostridium difficile in long-term-care facilities for the elderly. Infection Control and Hospital Epidemiology 23, Borriello, S. P. (1998). Pathogenesis of Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 41, Suppl. C, Wilcox, M. H. (1998). Treatment of Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 41, Suppl. C, Collignon, P. & Turnidge, J. (1999). Fusidic acid in vitro activity. International Journal of Antimicrobial Agents 12, Suppl. 2, S Oppenheimer, M., Kronvall, G., Karlsson, I. et al. (2000). Fusidic acid disk diffusion testing of Clostridium difficile can be calibrated using single-strain regression analysis. Scandinavian Journal of Infectious Diseases 32, Cronberg, S., Castor, B. & Thoren, A. (1984). Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. Infection 12, Wenisch, C., Parschalk, B., Hasenhundl, M. et al. (1996). Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhoea. Clinical Infectious Diseases 22, Teasley, D. G., Gerding, D. N., Olson, M. M. et al. (1983). Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet ii, Wilcox, M. H. & Howe, R. (1995). Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. Journal of Antimicrobial Chemotherapy 36,
6 M. Wullt and I. Odenholt 15. Gerding, D. N. (2000). Treatment of Clostridium difficileassociated diarrhoea and colitis. Current Topics in Microbiology and Immunology 250, Young, G. P., Ward, P. B., Bayley, N. et al. (1985). Antibioticassociated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 89, Dudley, M. N., McLaughlin, J. C., Carrington, G. et al. (1986). Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhoea. A randomised double-blind trial. Archives of Internal Medicine 146, de Lalla, F., Privitera, G., Rinaldi, E. et al. (1989). Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrobial Agents and Chemotherapy 33, Olson, M. M., Shanholtzer, C. J., Lee, J. T. et al. (1994). Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Centre, Infection Control and Hospital Epidemiology 15, Barbut, F. & Meynard, J. L. (2002). Managing antibiotic associated diarrhoea. British Medical Journal 324, Barbut, F., Decre, D., Burghoffer, B. et al. (1999). Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and Antimicrobial Agents and Chemotherapy 43, Wong, S. S., Woo, P. C., Luk, W. K. et al. (1999). Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagnostic Microbiology and Infectious Disease 34, Brazier, J. S., Fawley, W., Freeman, J. et al. (2001). Reduced susceptibility of Clostridium difficile to metronidazole. Journal of Antimicrobial Chemotherapy 48, Pelaez, T., Alcala, L., Alonso, R. et al. (2002). Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrobial Agents and Chemotherapy 46, Gerding, D. N. (1997). Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clinical Infectious Diseases 25, Suppl. 2, S Fekety, R. (1997). Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhoea and colitis. American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology 92, Verbist, L. (1990). The antimicrobial activity of fusidic acid. Journal of Antimicrobial Chemotherapy 25, Suppl. B, Freeman, C. D., Klutman, N. E. & Lamp, K. C. (1997). Metronidazole. A therapeutic review and update. Drugs 54, Tvede, M. & Rask-Madsen, J. (1989). Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet i, O Neill, A. J., Cove, J. H. & Chopra, I. (2001). Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 47, Ravenscroft, J. C., Layton, A. M., Eady, E. A. et al. (2003). Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (Fus R ) Staphylococcus aureus in atopic eczema. British Journal of Dermatology 148, Turnidge, J. & Collignon, P. (1999). Resistance to fusidic acid. International Journal of Antimicrobial Agents 12, Suppl.2, S Österlund, A., Edén, T., Olsson-Liljequist, B. et al. (2002). Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scandinavian Journal of Infectious Diseases 34,
Scottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationMAJOR ARTICLE. Antibiotic treatment is often associated with diarrhea and symptoms ranging from mild abdominal
MAJOR ARTICLE Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections Kathleen M. Mullane,
More informationAPPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.
APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAMEAND DOSAGE FORM: DALACIN C TM 150 mg (Capsules) COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin
More informationIntra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018
Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationHealthcare-associated Infections Annual Report December 2018
December 2018 Healthcare-associated Infections Annual Report 2011-2017 TABLE OF CONTENTS INTRODUCTION... 1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS... 2 MRSA SURVEILLANCE... 3 CLOSTRIDIUM
More information11/2/2015. Update on the Treatment of Clostridium difficile Infections. Disclosure. Objectives
Update on the Treatment of Clostridium difficile Infections Spencer H. Durham, Pharm.D.,BCPS (AQ-ID) Assistant Clinical Professor of Pharmacy Practice Auburn University Harrison School of Pharmacy Kurt
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationOverview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases
Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationIn vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in in Sweden
ORIGINAL ARTICLE BACTERIOLOGY In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993 2007 in Sweden T. Norén 1,2, I. Alriksson 2,T.Åkerlund 3, L. G. Burman
More informationCommunity-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018
Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationClostridium difficile Colitis
Update on Clostridium difficile Colitis Fredrick M. Abrahamian, D.O., FACEP Associate Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA
More informationInfection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be
Gastrointestinal Infections Infection Comments First Line Agents Penicillin Allergy History of multiresistant Campylobacter Antibiotics not recommended. Erythromycin 250mg PO 6 Alternative to first N/A
More informationCritical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary
Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationRunning head: CLOSTRIDIUM DIFFICILE 1
Running head: CLOSTRIDIUM DIFFICILE 1 Clostridium difficile Infection Christy Lee Fenton Mountainland Applied Technology College CLOSTRIDIUM DIFFICILE 2 Clostridium difficile Infection Approximately 200,000
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationTreatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals
Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with
More informationClostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU
Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU Disclosures I am not Tom Riley The Fidaxomicin guys brought me dinner once Outline ASID/AICA position
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Moser W, Coulibaly JT, Ali SM, et al.
More informationSynopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationStudy Protocol. Funding: German Center for Infection Research (TTU-HAARBI, Research Clinical Unit)
Effectiveness of antibiotic stewardship interventions in reducing the rate of colonization and infections due to antibiotic resistant bacteria and Clostridium difficile in hospital patients a systematic
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationReply to Fabre et. al
Reply to Fabre et. al L. Clifford McDonald, 1 Stuart Johnson, 2,3 Johan S. Bakken, 4 Kevin W. Garey, 5 Ciaran Kelly, 6 Dale N. Gerding, 2 1 Centers for Disease Control and Prevention, Atlanta, Georgia;
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationS aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium
S aureus infections: outpatient treatment Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium Intern Med J. 2005 Feb;36(2):142-3 Intern Med J. 2005 Feb;36(2):142-3 Treatment of
More information11-ID-10. Committee: Infectious Disease. Title: Creation of a National Campylobacteriosis Case Definition
11-ID-10 Committee: Infectious Disease Title: Creation of a National Campylobacteriosis Case Definition I. Statement of the Problem Although campylobacteriosis is not nationally-notifiable, it is a disease
More informationSrirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationAntibiotic therapy of acute gastroenteritis
Antibiotic therapy of acute gastroenteritis Potential goals Clinical improvement (vs control) Fecal eradication of the pathogen and decrease infectivity Prevent complications Acute gastroenteritis viruses
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationClostridium difficile
Clostridium difficile A Challenge in Long-Term Care Andrew E. Simor, MD, FRCPC Sunnybrook Health Sciences Centre University of Toronto Hosted by Paul Webber paul@webbertraining.com Objectives to understand
More informationIncidence of hospital-acquired Clostridium difficile infection in patients at risk
Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida All Publications 5-20-2016 Incidence of hospital-acquired Clostridium difficile infection in patients at risk Christine Ibarra
More informationThe Epidemiology Of Clostridium Difficile Infections Among Oncology Patients
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Public Health Theses School of Public Health January 2015 The Epidemiology Of Clostridium Difficile Infections Among Oncology
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 8. Prophylactic antibiotics for insertion of peritoneal dialysis catheter
8. Prophylactic antibiotics for insertion of peritoneal dialysis catheter Date written: February 2003 Final submission: May 2004 Guidelines (Include recommendations based on level I or II evidence) Antibiotic
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationECOLOGICAL IMPACT OF NARROW SPECTRUM ANTIMICROBIAL AGENTS COMPARED TO BROAD SPECTRUM AGENTS ON THE HUMAN INTESTINAL MICROFLORA CARL ERIK NORD
Old Herborn University Seminar Monograph 3: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. Editors: Carl Erik Nord, Peter J. Heidt, Volker Rusch, and
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationInterventions for children with ear discharge occurring at least two weeks following grommet(ventilation tube) insertion(review)
Cochrane Database of Systematic Reviews Interventions for children with ear discharge occurring at least two weeks following grommet(ventilation tube) insertion(review) Venekamp RP, Javed F, van Dongen
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationAntimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates
ORIGINAL ARTICLE BACTERIOLOGY Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates L. T. Erikstrup 1,2, T. K. L. Danielsen
More informationNew Insights into the Treatment of Leishmaniasis
New Insights into the Treatment of Leishmaniasis Eric Zini Snow meeting, 14 March 2009 Few drugs available for dogs Initially developed to treat human leishmaniasis, later adopted in dogs None eradicates
More informationA Prospective Investigation of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic
AAC Accepts, published online ahead of print on 14 November 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01608-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationCephalosporins, Quinolones and Co-amoxiclav Prescribing Audit
Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit Executive Summary Background Antibiotic resistance poses a significant threat to public health, as antibiotics underpin routine medical practice.
More informationAnaerobic and microaerophilic gram-positive cocci Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci
CLINDACIN Composition Each capsule contains Clindamycin (as hydrochloride) 150 mg Capsule Action Clindamycin bind exclusively to the 50S subunit of bacterial ribosomes and suppress protein synthesis. Clindamycin
More informationTHE VETERINARIAN'S CHOICE. Compendium clinical Trials. Introducing new MILPRO. from Virbac. Go pro. Go MILPRO..
THE VETERINARIAN'S CHOICE. Introducing new MILPRO from Virbac. Compendium clinical Trials Go pro. Go MILPRO.. milbemycin/praziquantel Content INTRODUCTION 05 I. EFFICACY STUDIES IN CATS 06 I.I. Efficacy
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationTreating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.
Treating Rosacea in the Era of Bacterial Resistance This presentation is sponsored by Galderma Laboratories, L.P. Lecture Discuss rosacea as an inflammatory condition Assess the psychosocial impact of
More informationCellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018
Cellulitis Assoc Prof Mark Thomas Conference for General Practice Auckland Saturday 28 July 2018 Summary Cellulitis Usual treatment flucloxacillin for 5 days Frequent recurrences consider penicillin 250mg
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationGeorgia State University. Georgia State University. Zirka Thompson. Spring
Georgia State University ScholarWorks @ Georgia State University Public Health Theses School of Public Health Spring 5-11-2012 Comparison of Risk Factors for Clostridium Difficile Infection Among Community
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated
More informationClinical Spectrum of Disease. Clinical Features. Risk Factors. Risk of CDAD According to Antibiotic Class. Fluoroquinolones as Risk Factor for CDAD
Clinical Features Range from mild diarrhea to severe colitis and death Common clinical symptoms include Watery diarrhea Fever Loss of appetite Nausea Abdominal pain/tenderness Less common ileus CDC Fact
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationSURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS
SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if
More informationEffectiveness of doxycycline for lyme disease
Effectiveness of doxycycline for lyme disease The Borg System is 100 % Effectiveness of doxycycline for lyme disease Mar 30, 2016. How long to treat patients with Lyme remains an issue of controversy.
More informationGuidelines for Antimicrobial treatment for treatment of confirmed infections adults
Guidelines for Antimicrobial treatment for treatment of confirmed infections adults This guideline gives recommendations for treatment of confirmed infections in adults for children please see the Paediatric
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationTreatment of peritonitis in patients receiving peritoneal dialysis Antibiotic Guidelines. Contents
Treatment of peritonitis in patients receiving Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Jude Allen (Pharmacist) Additional author(s): Dr David Lewis, Dr Dimitrios Poulikakos,
More informationReview: topical mupirocin or fusidic acid may be more effective than oral antibiotics for limited non-bullous impetigo
Treatment Review: topical mupirocin or fusidic acid may be more effective than oral antibiotics for limited non-bullous impetigo James H Larcombe (Commentator) Dr S Koning, Department of General Practice,
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationClostridium difficile infection: The Present and the Future
Clostridium difficile infection: The Present and the Future Carlos E. Figueroa Castro, MD Assistant Professor, Division of Infectious Diseases Medical College of Wisconsin November 2014 I have made this
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationAntibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients.
Antibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients. Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience,
More informationEffect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms in the intestinal microflora
Journal of Antimicrobial Chemotherapy (2004) 54, 791 797 DOI: 10.1093/jac/dkh406 Advance Access publication 25 August 2004 Effect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More informationClostridium Difficile Primer: Disease, Risk, & Mitigation
Clostridium Difficile Primer: Disease, Risk, & Mitigation KALVIN YU, M.D. CHIEF INTEGRATION OFFICER, SCPMG/SCAL KAISER PERMANENTE ASSOCIATE PROFESSOR INFECTIOUS DISEASE, COLLEGE OF GLOBAL PUBLIC HEALTH,
More informationAlfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach
Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach Historical overview The myriad causes of hospital acquired diarrhea Microbiology and ecology of Clostridium
More informationTHERAPY OF ANAEROBIC INFECTIONS LUNG ABSCESS BRAIN ABSCESS
THERAPY OF ANAEROBIC INFECTIONS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu LUNG ABSCESS A lung abscess is a localized pus cavity in
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationAntimicrobial prophylaxis. Bs Lưu Hồ Thanh Lâm Bv Nhi Đồng 2
Antimicrobial prophylaxis Bs Lưu Hồ Thanh Lâm Bv Nhi Đồng 2 Definition The United States Centers for Disease Control and Prevention (CDC) has developed criteria that define surgical site infection (SSI)
More informationLA-MRSA in Norway. One Health Seminar 27 June 2017, Ålesund
LA-MRSA in Norway One Health Seminar 27 June 2017, Ålesund Petter Elstrøm, Norwegian Institute of Public Health Merete Hofshagen, Norwegian Veterinary Institute Outline Background Epidemiology of MRSA
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationIn vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain
J Antimicrob Chemother 2015; 70: 2311 2315 doi:10.1093/jac/dkv092 Advance Access publication 15 April 2015 In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium
More informationOptimizing Antibiotic Treatment of Skin and Soft Tissue Infections
Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections 15th Annual Rocky Mountain Hospital Medicine Symposium November 6, 2017 Tim Jenkins, MD Director, Antibiotic Stewardship Program Denver
More information